CASI Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

CASI Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last three years, CASI Pharmaceuticals's Revenue has grown, moving from $15.14M to $33.88M – an increase of 123.78%. In the next year, analysts predict that Revenue will jump to $82.38M – up 143.15% from the current level. Looking ahead to seven years, experts forecast that Revenue will grow by 591.29%.

CASI Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

CASI Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

CASI Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, CASI Pharmaceuticals has seen a decline in its EBITDA, from $-31.35M to $-21.54M – a 31.29% decrease. In the coming year, analysts are expecting an increase in EBITDA, predicting it will reach $-24.73M – an increase of 14.82%. Over the next seven years, experts anticipate that EBITDA growth for CASI Pharmaceuticals will be 21.59%.

CASI Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last three years, CASI Pharmaceuticals's EBIT has decreased by 24.11%, from $-33.31M to $-25.28M. For the next year, 1 analysts project CASI Pharmaceuticals's EBIT to drop by 40.15%, reaching $-15.13M. By 2030, professionals believe that CASI Pharmaceuticals's EBIT will decrease by 189.28%, reaching $22.57M – a concerning trend for the company.

CASI Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, CASI Pharmaceuticals's EPS has grown, moving from $-2.76 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $-0.57 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.